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The modulation of mRNA turnover is gaining recognition as a mechanism by which Staphy-
lococcus aureus regulates gene expression, but the factors that orchestrate alterations
in transcript degradation are poorly understood. In that regard, we previously found that
138 mRNA species, including transcripts coding for the virulence factors protein A (spa)
and collagen-binding protein (cna), are stabilized in a sarA-dependent manner during expo-
nential phase growth, suggesting that SarA directly or indirectly affects the RNA turnover
properties of these transcripts. Herein, we expanded our characterization of the effects of
sarA on mRNA turnover during late-exponential and stationary phases of growth. Results
revealed that the locus affects the RNA degradation properties of cells during both growth
phases. Further, using gel mobility shift assays and RIP-Chip, it was found that SarA protein
is capable of binding mRNA species that it stabilizes both in vitro and within bacterial cells.
Taken together, these results suggest that SarA post-transcriptionally regulates S. aureus
gene expression in a manner that involves binding to and consequently altering the mRNA
turnover properties of target transcripts.
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INTRODUCTION
Staphylococcus aureus is a human pathogen that causes nosoco-
mial and community-associated infections that result in high rates
of morbidity and mortality (Klevens et al., 2007; Deleo et al.,
2010). The organism largely owes its ability to cause infection
to the production of an array of virulence factors which, in the
laboratory setting, are coordinately regulated in a cell density-
dependent manner. Cell surface-associated factors are predomi-
nantly expressed during exponential phase growth whereas extra-
cellular factors are predominantly produced during stationary
phase growth (Novick, 2003; Bronner et al., 2004). The organ-
ism’s virulence factors are also coordinately regulated in response
to endogenous and exogenous cues, including cellular stresses and
sub-inhibitory concentrations of antibiotics. A plethora of two
component regulatory systems (TCRS) and nucleic acid-binding
proteins have been hypothesized to modulate S. aureus virulence
factor expression.
Of the 17 TCRS identiﬁed in S. aureus to date, the best-
characterized is the accessory gene regulator (agr) locus. The agr
locus encodes a quorum-sensing TCRS, AgrAC, whose regulatory
effects are generally thought to be mediated by a regulatory RNA
molecule, RNAIII. Within laboratory culture conditions, RNAIII
expression peaks during the transition to stationary phase growth
(Novick, 2003). RNAIII has been shown to modulate virulence
factor expression by directly binding to target mRNA species,
thereby affecting their stability and translation properties (Mor-
feldt et al., 1995; Huntzinger et al., 2005; Geisinger et al., 2006;
Boisset et al., 2007). For instance,RNAIII binding to the cell surface
factor protein A (spa) transcript creates a substrate for ribonucle-
ase III digestion, which, in-turn, accelerates spa mRNA digestion
and consequently limits Spa production (Huntzinger et al., 2005).
Conversely, the binding of RNAIII to the extracellular virulence
factor α-hemolysin (hla) transcript liberates the mRNA’s Shine–
Dalgarno sequence and increases Hla production (Morfeldt et al.,
1995). Similar mechanisms of RNAIII regulation have been doc-
umented for the virulence factor coa (Chevalier et al., 2010) and
the regulatory locus repressor of toxins (rot ; Boisset et al., 2007).
In addition to TCRS, S. aureus produces a family of DNA-
binding proteins that regulate virulence factor expression. The
best-characterized to date is the staphylococcal accessory regula-
tor nucleic acid-binding protein, SarA. The sarA locus consists of a
1.2 kbDNAregion that produces three overlapping transcriptional
units (sarB, sarC, and sarA), each of which terminates at the same
site and encodes for the SarA protein (Chien and Cheung, 1998).
Unlike RNAIII, SarA is constitutively produced throughout S.
aureus growth phases, however the expression of the individual sar
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transcripts occurs in a growth phase-dependentmanner; sarA and
sarB are primarily transcribed during exponential phase growth
whereas sarC is predominantly expressed during stationary phase
growth (Manna et al., 1998; Blevins et al., 1999). SarA has been
characterized as a pleiotropic transcriptional regulator of virulence
factors that can bind to the promoter regions of a subset of genes
that it regulates, such as hla (α-hemolysin) and spa (protein A;
Chien and Cheung, 1998; Chien et al., 1999). Nonetheless, several
observations have suggested that SarA’s regulatory effects might be
more complex than initially appreciated. Arvidson and colleagues
have reported that, in addition to affecting spa transcript synthe-
sis, SarA may also indirectly regulate Spa production (Tegmark
et al., 2000). Further, no clear SarA consensus binding site has
been deﬁned; Cheung and colleagues found that SarA binds a 26
base pair (bp) region termed the SarA box, whereas Sterba et al.
(2003) have deﬁned the SarA box to be a 7 bp sequence, which
is present more than 1000 times within the S. aureus genome,
indicating that the protein may have the capability of binding the
chromosome more frequently than one might expect for a bona
ﬁde transcription factor (Chien et al., 1999). In that regard, others
have suggested that SarA is a histone-like protein whose regulatory
effects are a function of altering DNA topology and, consequently,
promoter accessibility (Schumacher et al., 2001).
InEscherichia coli, histone-like proteins can post-transcription-
ally regulate gene expression by binding directly to mRNA mol-
ecules and inﬂuencing the transcript’s stability and translation
(Balandina et al., 2001; Brescia et al., 2004). Accordingly, based on
the possibility that SarA may behave as a histone-like protein, we
hypothesized that the protein’s regulatory effects may, in part, be
due to its ability to bind and subsequently modulate the mRNA
turnover properties of target transcripts. As a ﬁrst step toward
testing that prediction, we found that 138 mRNA species that are
produced during S. aureus exponential phase growth, including
the known SarA-regulated genes spa and cna, are also stabilized
in a sarA-dependent manner (Roberts et al., 2006). More speciﬁ-
cally, thesemRNA transcripts are stabilized in a sarA+ background
as compared to isogenic sarA− cells, raising the possibility that
SarA protein may bind these transcripts in a manner that affects
their stability and, consequently, expression. In the current body of
work we extended our evaluation of this phenomenon by investi-
gating whether the mRNA turnover properties of late-exponential
and/or stationary phase transcripts are also modulated in a sarA-
dependent manner. Results revealed that this is indeed the case;
the sarA locus affects themRNA turnover properties of transcripts
produced during both phases of growth. Further, using ribonucle-
oprotein immunoprecipitation (RIP-Chip) assays, we found that
SarA binds these transcripts within S. aureus cells. Results were
veriﬁed via gel-shift mobility assays. Taken together, these results
indicate that SarA is capable of binding cellular mRNA species
and that the protein’s regulatory effects could be attributable to
its ability to directly modulate the mRNA turnover properties of
target mRNA species.
MATERIALS AND METHODS
GROWTH CONDITIONS
Bacterial strains and plasmids used in this study are listed in
Table 1. Overnight S. aureus cultures were diluted 1:100 into
Table 1 | Bacterial strains and plasmids used in this study
Strains Relevant genotype or
phenotype
Reference
UAMS-1 Wild type S. aureus
osteomyelitis isolate
Gillaspy et al. (1995); Cas-
sat et al. (2005)
UAMS-929 UAMS-1 (ΔsarA) Blevins et al. (1999)
KLA43 UAMS-929 (pKLA40) This study
RN4220 Restriction-deﬁcient S. aureus de Azavedo et al. (1985)
INVαF E. coli competent cells;
lacZΔM15
Invitrogen
DH5α E. coli competent cells Invitrogen
Plasmids Relevant genotype
pCRII TOPO-TA cloning vector Invitrogen
pBK123 CamR derivative of pCN51 Charpentier et al. (2004)
pKLA40 pBK123::c-Myc-SarA This study
fresh brain–heart infusion (BHI) broth with a ﬂask to volume
ratio of 5:1 and were incubated at 37oC with aeration on a
rotary shaker at 225 rpm.When cultures reachedmid-exponential
(OD600 nm = 0.25–0.30), late-exponential (OD600 nm = 1.1–1.2),
or stationary (24 h post-inoculation) phase, rifampicin (200μg
ml−1; Sigma; St. Louis, MO) was added to arrest transcription.
Aliquots of cells were removed at 0, 2.5, 5, 15, and 30min post-
transcriptional arrest, mixed with an equi-volume of ice-cold ace-
tone:ethanol (1:1) and RNA was isolated, as previously described
(Anderson et al., 2006; Roberts et al., 2006; Olson et al., 2011).
GENECHIP® MICROARRAYS
All microarray studies were performed as previously described
(Anderson et al., 2006, 2010; Roberts et al., 2006; Olson et al.,
2011). Brieﬂy, 10μg of each bacterial RNA sample was labeled and
hybridized to a S. aureus GeneChip®, following themanufacturer’s
recommendations for antisense prokaryotic arrays (Affymetrix;
Santa Clara, CA). Average GeneChip®signal intensities for biolog-
ical replicates (n ≥ 2) for each strain and time point were obtained
from values normalized to exogenous transcripts. The half-life
of each RNA transcript was determined using a “twofold” algo-
rithm (Selinger et al., 2003) and was measured as the time point
at which a given RNA signal intensity decreased two-fold as com-
pared to that transcript at 0min post-transcriptional arrest using
GeneSpring 7.2 software (Agilent Technologies; Redwood City,
CA).
IN VITRO TRANSCRIPTION
DNA templates consisting of the full-length spa transcriptional
unit or derivatives containing 3′ or 5′ deletions were created
by PCR ampliﬁcation using UAMS-1 chromosomal DNA as a
template and oligonucleotides listed in Table 2. Resulting PCR
products contained a 5′ T7 RNA polymerase promoter and tran-
scription start site andwere used as templates for generating corre-
sponding RNA species using a T7 MegaScript In vitro Transcrip-
tion Kit (Ambion; Austin, TX) according to the manufacturer’s
recommendations. Brieﬂy, for transcription reactions, approxi-
mately 1μg of PCR product was incubated for 3 h at 37oC with
7.5mM of a NTP mix and T7 RNA polymerase to generate the
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Table 2 | Oligonucleotides used in this study
Primer name Sequence (5′ →3′)
RT-PCR
cna F AACGAACAAGTATACACCAGGAGAG
cna R TTTGCTTTTTCATCTAATCCTGTC
norA F GCAGGTGCATTAGGCATTTTAGC
norA R TGCCGATAAACCGAACGCTAAG
spa F GCAGAAGCTAAAAAGCTAAATGATG
spa R GCTCACTGAAGGATCGTCTTTAAGG
sarA F TTTTAACCATGGCAATTACAAAAAT
sarA R TTTCTCTTTGTTTTCGCTGATGTAT
PCR-MEDIATED INVITRO TRANSCRIPTION*
L 1–450 spa T7 F TAATACGACTCACTATAGGGCATACAGGGGGTATTAATTTGAAAA
L 1–450 spa R ATCCTAGAATTCTCTTCGTTCAAGTTAGGCATGTTCA
L −250 spa T7 F TAATACGACTCACTATAGGGGTTCAACAAAGATCAACAAAGCGCC
L −250 spa R AGTAGAAAGTGTTGAGGCGTTTCAG
CLONING
†,‡
c-Myc-SarA F ATCCTAGTCGACGCTAACCCAGAAATACAATCACTGTGTC
c-Myc-SarA R ATCCTAGGATCCTTACAGATCTTCTTCGCTGATCAGTTTCTGTTCTA GTTCAATTTCGTTGTTTGCTTCAGTG
*Bolded nucleotides indicate T7 promoter sequence.
† Underlined nucleotides indicate restriction sites.
‡ Italicized nucleotides indicate the c-Myc epitope.
indicated RNA species. Template DNA was degraded with four
units of TurboDNase I for 15min at 37oC, and in vitro transcribed
RNA was recovered by lithium chloride precipitation and resus-
pended in nuclease-free water. RNA concentration of the synthe-
sized product was determined spectrophotometrically (OD260 nm
1.0= 40μgml−1) and the integrity of the transcript was evaluated
on a 1.2% agarose–0.66M formaldehyde denaturing gel.
ELECTROPHORETIC MOBILITY SHIFT ASSAY
In vitro transcribed spa mRNA or a PCR product contain-
ing the endogenous hla promoter were 3′ end-labeled with
digoxigenin-ddUTP (DIG; Roche Applied Science; Indianapolis
IN) following the manufacturer’s recommendations. One pico-
mole DIG-mRNA or -DNA was mixed with 0, 7.3, 36.6, 73.3,
or 366.5 pmol puriﬁed SarA protein then, incubated for 15min
at 37oC in gel-shift buffer (20mM HEPES-KOH, pH 8.0, 8mM
MgCl2, 100mM NaCl), cooled on ice and the entire sample
volume was electrophoresed in 1.2% agarose–0.66M formalde-
hyde denaturing gels. Next, RNA-protein or DNA-protein com-
plexes were transferred via capillary action to nylon membranes
overnight in 20× SSC buffer (3M NaCl, 300mM sodium cit-
rate, pH 7.0). Nucleic acid was then cross-linked to the mem-
brane by UV irradiation in a Stratalinker®UV crosslinker (Strat-
agene; La Jolla, CA) twice at 1200 (×100) microjoules. Mem-
branes were probed for presence of the DIG-labeled RNA or
DNA using anti-DIG Fab fragments conjugated to alkaline phos-
phatase (1:10,000; Roche Applied Science) and visualized chemi-
luminescently with CSPD reagent (Roche Applied Science). For
all binding assays, bovine serum albumin (BSA) was used as a
negative control for non-speciﬁc RNA-protein and DNA-protein
interactions.
c-Myc-SarA CONSTRUCTION
A c-Myc epitope was translationally fused to the C-terminus of
the SarA open reading frame. To do so, 615 bp of the S. aureus
strain UAMS-1 sarA gene and its corresponding P1 promoter
region were ampliﬁed by PCR using primers c-Myc-SarA F and
c-Myc-SarA R (Table 2); the latter included a c-Myc epitope and
3′ ﬂanking restriction enzyme site. The resultant PCR product
was gel-puriﬁed and digested with restriction enzymes SalI and
BamHI and subcloned into pBK123 (Charpentier et al., 2004) to
generate the plasmid pKLA40. Plasmid pKLA40 was then electro-
porated into the restriction-negative strain of S. aureus, RN4220
(de Azavedo et al., 1985) and transfected into UAMS-929 (ΔsarA)
viaϕ11-mediated phage to generate strain KLA43 and the plasmid
was sequenced to conﬁrm the integrity of the insert. c-Myc-
SarA functionality was conﬁrmed by examining the ability of the
epitope-tagged protein to complement the exoprotein proﬁle of
UAMS-929(ΔsarA) cells. Brieﬂy, supernates from stationary phase
cultures of S. aureus UAMS-1, UAMS-929(ΔsarA), and KLA43
(ΔsarA; c-Myc-SarA) were collected, ﬁltered through a 0.22μm
nylon membrane, and compared by electrophoresis in sodium
dodecyl sulfate-polyacrylamide gels and silver staining (Bio-Rad
Life Science, Hercules, CA).
WESTERN BLOTTING
Cultures were grown to the indicated growth phase and cells were
mechanically disrupted in TE buffer in BIO101 lysing matrix B
tubes using a FastPrep120 shaker (MP Biomedicals; Solon OH).
Cell debris was removed by centrifugation at 4oC for 15min
and the protein concentration of supernatants were quantiﬁed by
Bradford protein assays. For conﬁrmation of c-Myc-SarA expres-
sion, 1μg of proteinwas electrophoresed in a 15% sodiumdodecyl
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sulfate-polyacrylamide gels and transferred to polyvinylidene ﬂu-
oride membranes. Membranes were blocked with 10% milk in
Tween-TBS (TTBS; TBS containing 0.1% Tween 20) and rabbit
polyclonal anti-c-Myc antibody (1:1000; Sigma Aldrich; St. Louis,
MO) was used to probe for presence of the c-Myc-SarA pro-
tein. Following incubationwith the primary antibody,membranes
were washed in TTBS and probed with peroxidase-conjugated
anti-rabbit secondary antibody (1:1000; Promega; Madison, WI).
Membranes were washed and c-Myc-SarA was detected chemilu-
minescently by ECLTM (Amersham BioSciences; Piscataway NJ).
Conﬁrmation of successful RIP was conﬁrmed by loading 10μl of
cell lysate, cell supernate, wash, or elution fractions and subjected
to SDS-PAGE and western blotting, as described above.
RIBONUCLEOPROTEIN IMMUNOPRECIPITATION (RIP-Chip)
Ribonucleoprotein immunoprecipitation was performed using a
c-Myc Tag/Co-IP Kit (Pierce Biotechnology; Rockford, IL). To
do so, S. aureus strains UAMS-929 (ΔsarA; negative control)
and KLA43 (ΔsarA/pKLA40::c-Myc-SarA) were grown to mid-
exponential phase and RNA-binding proteins were cross-linked
to RNA by incubating the cells for 30min with 1% formalde-
hyde at room temperature. Cross-linking was quenched by adding
125mM glycine for 5min at room temperature. Cells were cen-
trifuged at 3000 RPM for 10min at 4oC and cell pellets were
washed twice in 1ml ice-cold TBS, resuspended in 350μl of lysis
buffer (10mMTris pH 8.0, 10mMEDTA, 50mMNaCl, and 1mM
PMSF) and were lysed by the addition 100μg ml−1 lysostaphin
(Ambi; Lawrence, NY) at 37oC for 30min. Next, an equal vol-
ume of 2× immunoprecipitation (IP) buffer (100mMTris pH 8.0,
10mM EDTA, 300mM NaCl, 2% Triton X-100, 1mM PMSF) was
added and suspensions were incubated for an additional 10min
at 37oC. Nucleic acids were fragmented with a Sonic Dismem-
brator (Fisher) on ice twice for 15 s using an output setting of
one with 15 s rests on ice between each pulse and cell debris was
subsequently removed by centrifugation for 10min at 4oC. Next,
800μl of the supernatant was mixed with 10μl of anti-c-Myc
agarose (Pierce Biotechnology; Rockford IL) and then added to IP
spin columns (Pierce Biotechnology) and incubated overnight at
4oC to collect c-Myc-SarA/RNA and DNA complexes. Columns
were washed ﬁve times with 1× IP buffer and c-Myc-SarA com-
plexes were eluted in 50μl of elution buffer (50mM Tris pH 8.0,
10mM EDTA, 1% SDS) by ﬁrst incubating at 65oC for 10 in fol-
lowed by centrifugation at 4oC to collect eluate. Cross-linking
was reversed by incubating eluate for 2 h at 42oC and then 6 h at
65oC in 0.5× elution buffer containing 0.8mg ml−1 pronase. For
chromatin immunoprecipitation (ChIP-chip) experiments used
to detect known SarA-DNA interactions, liberated DNA was puri-
ﬁed using a PCR Clean-Up Kit (Qiagen) per manufacturer’s rec-
ommendations and hybridized to a GeneChip®and processed as
described above. For RIP-chIP experiments, liberated nucleic acid
was treated with 17U of RNase-Free DNase I (Qiagen) and RNA
was puriﬁed using a Clean and Concentrator Kit (Zymo Research;
Orange, CA) according to the manufacturer’s recommendations.
All assays were performed in triplicate for each strain and puriﬁ-
cation of the c-Myc-SarA protein was conﬁrmed via Western
blotting. Following IP, bacterial RNA was ampliﬁed and reverse-
transcribed using a MessageAmp II-Bacteria Prokaryotic RNA
Ampliﬁcation Kit (Ambion). 1.5μg of the ampliﬁed cDNA was
then hybridized to a GeneChip®and processed as described above.
The fold change in average signal intensity of KLA43 replicates
as compared to the average signal intensity of UAMS-929 (nega-
tive control) replicateswas calculated for eachGeneChip®qualiﬁer.
SarA was considered to bind DNA or transcripts that exhibited a
signal intensity that was ≥ two-fold in KLA43 samples and greater
than two standard deviations from the average signal intensity
(background), as compared to UAMS-929 cells.
QUANTITATIVE REVERSE-TRANSCRIPTION PCR
For standard qRT-PCR reactions, 25 ng of total bacterial RNA
were reverse-transcribed, ampliﬁed, and measured using a Light-
Cycler®RNA Master SYBR Green I kit per the manufacturer’s
recommendations (Roche Applied Science). As an internal con-
trol by which to standardize RNA loading, 0.5 pg of RNA was
used to quantitate the amount of 16S rRNA in each sample. Tran-
script concentrations were calculated using LightCycler®software
and LightCycler®Control Cytokine RNA titration kit as a standard
for determining the copies of each transcript present per reac-
tion. Final concentration values are listed as normalized to 16S
rRNA abundance. Transcript half-lives were calculated as the time
point at which RNA titers exhibited a≥ two-fold decrease in signal
intensity.
RESULTS
It is well recognized that SarA is a pleiotropic regulator of S.
aureus virulence factors, yet the mechanism(s) by which the pro-
tein affects gene expression is incompletely understood. Several
studies have shown that themolecule affects the transcript synthe-
sis of target genes, however the lack of a consensus SarA-binding
sequence and evidence of indirect control of gene expression have
implicated SarA inpost-transcriptional control of gene expression.
Accordingly, it has also been hypothesized that SarA regulates S.
aureus gene expression via modulating the mRNA turnover prop-
erties of target transcripts. In support of this hypothesis, we have
previously shown that 138 mRNA species, including the virulence
factor transcripts protein A (spa) and collagen-binding protein
(cna) are stabilized in a sarA-dependent manner (Roberts et al.,
2006). Our current efforts are designed to expand upon these ini-
tial studies and further deﬁne the role for sarA in modulating
mRNA turnover.
sarA STABILIZES SUBSETS OF mRNA SPECIES IN A GROWTH
PHASE-DEPENDENT MANNER
Herein, we set out to establish whether the degradation proper-
ties of mRNA species that are expressed during late-exponential
and/or stationary phase growth are affected by a product of the
sarA locus. To do so, S. aureus UAMS-1 (wild type) and UAMS-
929 (UAMS-1ΔsarA) were grown to late-exponential or stationary
phase growth and transcription was halted by the addition of
rifampicin. Total bacterial RNAwas then puriﬁed from aliquots of
cells at 0, 2.5, 5, 15, and 30min post-transcriptional arrest and the
mRNA titers of expressed transcripts were then measured using
Affymetrix GeneChips®. A comparsion of each transcript’s titer at
0min post-transcriptional arrest to that of each subsequent time
point allowed the half-lives of each mRNA to be measured, as
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previously described (Anderson et al., 2006, 2010; Roberts et al.,
2006; Olson et al., 2011).
As shown inFigure 1, in general terms, the global RNA turnover
properties of UAMS-1 and UAMS-1ΔsarA cells exhibited a sim-
ilar trend that is consistent with our previous observations; bulk
mRNA turnover occursmore rapidly in exponential phase as com-
pared to stationary phase cells (Olson et al., 2011). Despite these
similarities, a more detailed analysis of RNA degradation proper-
ties of individual mRNA species within each strain background
indicated that sarA inﬂuences the stability of many transcripts.
More speciﬁcally, 93.2 and 48.4% of transcripts exhibited half-
lives of <2.5min during late-exponential and stationary phase
growth, respectively, in the wild type strain (Table 3). Conversely,
76.9 and 32.5% of transcripts were degraded within 2.5min in
late-exponential and stationary phase ΔsarA cells, suggesting that
FIGURE 1 | Global transcript turnover properties of wild type and
ΔsarA cells.The global RNA turnover properties of UAMS-1 (wild type) and
isogenic ΔsarA (ΔsarA) cells during late-exponential (LE) and stationary
phase (SP) growth are graphed. Percentages of total transcripts with
half-lives of ≤2.5, 2.5–5, 5–15, 15–30, and ≥30min are shown.
sarA affects the stability of a subset of transcripts.Within this sub-
set, 68 (3.2%; Supplemental Table S1 in Supplementary Material)
and 325 (15.3%; Supplemental Table S2 in Supplementary Mater-
ial) of late-log and stationary phase transcripts, respectively, were
less stable in ΔsarA cells, indicating that they are stabilized in a
sarA-dependent manner. Conversely, 385 (18.2%; Supplemental
Table S3 in Supplementary Material) and 580 (27.2%; Supple-
mental Table S4 in Supplementary Material) of transcripts were
more stable in ΔsarA cells, indicating that, like RNAIII, SarA may
facilitate degradation of a particular subset of mRNA species.
sarA AFFECTS VIRULENCE FACTOR mRNA STABILITY
Results also indicated that the mRNA turnover properties of
many virulence factors are inﬂuenced by sarA, but that these
effects predominantly occur during stationary phase growth.More
speciﬁcally, during late-exponential phase growth the transcripts
coding for three virulence-associated genes were stabilized in a
sarA-dependent manner (Table 4). Among these were two meta-
bolic enzymes, enolase (eno; Carneiro et al., 2004) and carbamate
kinase (arc ; Beenken et al., 2004; Diep et al., 2006; Diep and Otto,
2008), both of which exhibited half-lives of 30min in wild type
cells but only 15min in ΔsarA cells. Likewise, the ATP-dependent
protease clpP (Frees et al., 2003, 2005;Michel et al., 2006), exhib-
ited a half-life of 15min in wild type cells, but was reduced to ﬁve
min in the sarA-mutant. During stationary phase growth at least
13 virulence factor transcripts were stabilized in a sarA-dependent
manner (Table 4). Included among these were: spa (protein A),
hla (α-hemolysin), hlb (β-hemolysin), and hlgCB (γ-hemolysin),
aswell asmembers of the capsule operon (cap) and the cell surface-
associated factors fnbA (encoding ﬁbronectin binding protein
A) and cna (encoding a collagen-binding protein). Quantitative
RT-PCR-based determination of select virulence factor half-lives
within stationary phase wild type and ΔsarA cells veriﬁed the
microarray-based RNA turnover measures (Table 5). In addi-
tion to virulence factors, three virulence factor regulatory mol-
ecules, agrA, sarS, and saeS, were stabilized in a sarA-dependent
manner.
Table 3 | S. aureus growth phase mRNA degradation
UAMS-1 ΔsarA
Late-log Stationary Late-log Stationary
Transcripts Percentage Transcripts Percentage Transcripts Percentage Transcripts Percentage
≤2.5min 2044 93.2 1115 48.4 1620 76.9 691 32.5
2.5–5min 36 1.6 648 28.1 359 17.0 1032 48.5
5–15min 92 4.2 389 16.9 104 4.9 294 13.8
15–30min 16 0.7 103 4.5 9 0.4 69 3.2
>30min 4 0.2 47 2.0 15 0.7 40 1.9
Total 2192a 100 2302b 100 2107c 100 2126d 100
a55 RNA species could not be measured.
b27 RNA species could not be measured.
c38 RNA species could not be measured.
d18 RNA species could not be measured.
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Table 4 | sarA-stabilized virulence-associated transcripts
Common
name
†‡
Half-life* Description
Wild
type
ΔsarA
LATE-EXPONENTIAL
arcC 30min 15min Carbamate kinase
clpP 15min 5min ATP-dependent protease
eno 30min* 15min Enolase
spa
‡
Stable* Stable* Protein A
STATIONARY
agrA Stable* 30min AgrACTCRS response regulator
arcB 15min 5min Ornithine carbamoyltransferase
cap5A 5min 2.5min Capsular polysaccharide biosynthesis
cap5C 15min 5min Capsular polysaccharide biosynthesis
cap5D 15min 5min Capsular polysaccharide biosynthesis
cna 15min 5min Collagen-binding protein
fnbA 15min 5min Fibronectin binding protein A
hla
‡
Stable 30min α-hemolysin
hlb 30min 15min Phospholipase C
hlgB 30min 15min γ hemolysin component B
hlgC 15min 5min γ hemolysin component C
norA 15min 5min Multi drug transporter
rsbV 5min 2.5min Anti–anti-sigma factor
SACOL0390 Stable 30min Lipase
saeR 15min* 5min SaeRSTCRS response regulator
sarV 5min 2.5min SarA homolog
spa
‡
30min* 15min* Protein A
*Estimated half-life due to detection limits of the system.
† S. aureus strain N315 loci unless otherwise noted.
‡Transcript synthesis affected by sarA in UAMS-1 cells (Cassat et al., 2006).
SarA BINDS mRNA IN VITRO
The results presented here are consistent with previous obser-
vations suggesting that the sarA locus affects S. aureus mRNA
turnover properties with exponential phase cells (Roberts et al.,
2006). The two most likely scenarios that could account for these
observations are that a product of the sarA locusmaydirectly inter-
actwith and subsequently affect themRNAdegradation properties
of target transcripts or that SarA indirectly modulates the organ-
ism’s mRNA turnover properties by regulating other factors that
affect S. aureus RNAdecay. As a preliminarymeans of distinguish-
ing between these twopossibilities we set out to determinewhether
SarA is an RNA-binding protein. To do so, electrophoretic mobil-
ity shift assays (EMSAs) were performed to investigate whether
puriﬁed SarA protein directly binds to spa transcripts, an mRNA
species that is stabilized in a sarA-dependent manner (Roberts
et al., 2006). Accordingly, various amounts (0, 7.3, 36.6, 73.3,
or 366.5 pmol) of puriﬁed SarA protein were incubated with
DIG-labeled, in vitro transcribed spa mRNA, during experimental
conditions that have previously been used to establish that SarA
binds to the promoter region of theα-hemolysin (hla) gene (Chien
et al., 1999). As shown in Figure 2A, during these assay condi-
tions SarA protein did indeed bind to the hla promoter region,
Table 5 | Stationary phase mRNA half-lives of selected virulence factor
transcripts as calculated by qRT-PCR*
Wild type
†
ΔsarA
†
spa
0min 1.00 1.00
5min 1.06 1.34
15min 1.22 1.63
30min 2.43 5.56
60min 2.47 11.28
norA
0min 1.00 1.00
5min 1.45 3.14
15min 2.20 3.22
30min 3.14 6.99
60min 3.20 5.38
cna
0min 1.00 1.00
5min 1.02 2.49
15min 2.68 2.07
30min 18.66 6.22
60min 83.91 35.33
*Time point corresponding to ≥ two-fold decrease (half-life) is shaded gray.
†Values represented as fold-change normalized to mRNA titers at 0min.
conﬁrming that the experimental conditions are appropriate to
measure SarA-nucleic acid interactions and further validating the
work of Chien et al. (1999). Similarly, the EMSA revealed that SarA
elicited a dose-dependent shift in mobility of labeled spa mRNA,
suggesting that SarA may be capable of binding RNA molecules
(Figure 2B). Gel-shift assays were also performed with BSA and a
S. aureus stable RNA, SSR42 (Olson et al., 2011), to determine if
non-staphylococcal proteins would bind to the in vitro transcribed
mRNA and whether SarA alters the mobility of any RNA species,
respectively. Results of those studies indicated that BSA did not
affect the mobility of spa transcript and, likewise, that SarA did
not affect themigration of in vitro transcribed SSR42 (Figure 2C).
RNA-binding proteins have been shown to bind to speciﬁc
regions of target mRNAs (Folichon et al., 2003;Wang et al., 2005);
to test this possibility with SarA, we used EMSAs to measure the
protein’s ability to bind different regions of in vitro transcribed spa
mRNA: a region lacking bases 1–320 of the 5′ end (L-250) and a
fragment of spa containing only bases 1–450 (L 1–450;Figure 2D).
As seen in Figure 2E, SarA affected the mobility of both RNA
species. Further, a higher molecular weight product was observed
when SarA was incubated with spa RNA fragments containing an
intact 5′region (450 nt) in comparison to fragments lacking bases
1–250 of the transcript (1,100 nt), suggesting that the 5′ end of
the spa transcript may harbor a greater number of SarA-binding
sites than the 3′ terminus. Taken together, these results suggest that
SarA may be capable of binding both DNA and RNA molecules.
SarA BINDS mRNA IN VIVO
Based on the observations that many exponential phase tran-
scripts, including spa, are stabilized in a sarA-dependent manner
and that SarA protein is capable of altering the mobility of spa
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FIGURE 2 | SarA binds mRNA in vitro. (A) Gel mobility shift assays
evaluating the mobility of DIG-labeled hla promoter DNA (Phla) in the presence
of increasing amounts of puriﬁed SarA protein (0, 7.3, 36.6, 73.3, or
366.5 pmol). (B) Gel mobility shift assays evaluating the mobility of
DIG-labeled, in vitro transcribed spa in the presence of increasing
concentrations of SarA protein (0, 7.3, 36.6, 73.3, or 366.5 pmol). (C) Gel
mobility shift assays evaluating the mobility of DIG-labeled, in vitro
transcribed SSR42 in the presence of increasing concentrations of SarA
protein (0, 36.6, 73.3, or 366.5 pmol). (D) Schematic of transcript variants
containing deletions of 3′ or 5′ regions of spa that were DIG-labeled for use in
subsequent gel-shift assays. (E) Gel mobility shift assays evaluating the
mobility DIG-labeled spa deletion variants in the presence of 73.3 pmol SarA.
transcripts in vitro, we set out to determine whether the protein
is capable of binding mRNA species within bacterial cells using
ribonucleoprotein immunoprecipitation-microarray (RIP-Chip)
assays. To do so, we needed to create a means of capturing cellular
SarA protein. Accordingly, the SarA open reading framewas trans-
lationally fused to a C-terminal c-Myc epitope. This construct was
placed under control of the sarA endogenous P1 promoter and
was inserted into plasmid pCN51 to generate pKLA40. This plas-
mid was transfected into UAMS-929 (ΔsarA) cells to generate
strain KLA43 and the expression properties of C-Myc-SarA pro-
tein were evaluated. It should be noted that the c-Myc epitope
has been shown to exhibit little or no non-speciﬁc nucleic acid
binding in previous assays (Pannone et al., 1998). As expected,
RT-PCR and Western blotting using anti-c-Myc antibodies estab-
lished that the chimeric protein was expressed within KLA43 cells
(Figures 3A,B) during mid- and late-exponential as well as sta-
tionary phase growth. We also conﬁrmed that c-Myc-SarA was
capable of complementing SarA’s regulatory effects within ΔsarA
cells. Speciﬁcally, sarA-mutant cells have been reported as exhibit-
ing altered exprotein proﬁles due to alterations in the control of
gene expression (Tegmark et al., 2000). Thus, we evaluated the
ability of the c-Myc-SarA construct to complement the exopro-
tein proﬁle of supernates from stationary phase cultures of S.
aureus strain UAMS-929 (ΔsarA). As shown in Figure 3C, the
c-Myc-SarA construct at least partially complemented the exopro-
tein proﬁle of ΔsarA cells, indicating that presence of the epitope
did not signiﬁcantly affect SarA’s regulatory capacity and, conse-
quently, the chimeric protein was appropriate for studying SarA’s
cellular role as an RNA-binding protein.
Having conﬁrmed that the chimeric protein was expressed and
functional within ΔsarA cells, RIP-chIP assays were performed
using anti-c-Myc immunoglobulin immobilized on agarose beads
to capture cellular c-Myc-SarA-bound transcripts. To do so,
KLA43 (ΔsarA c-Myc-SarA) was grown tomid-exponential phase
and the proteins were cross-linked to nucleic acids with 1%
formaldehyde to stabilize any interactions between c-Myc-SarA
and RNA molecules. Cells were lysed and c-Myc-SarA protein
was then immunoprecipitated with the anti-c-Myc agarose beads,
co-precipitating any bound RNA species. Western blotting of the
cell lysates and RIP intermediates indicated the presence of the
epitope-labeled SarA through sequential steps of the IP process
(Figure 3D). After reversal of the RNA cross-linking, the RNAwas
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FIGURE 3 | SarA binds mRNA in vivo. (A) RT-PCR based detection of
c-Myc-SarA transcript expression in ΔsarA and ΔsarA harboring plasmid
pKLA40 harboring a c-Myc-SarA construct under control of the sarA P1
promoter during mid-exponential (ME), late-exponential (LE), and stationary
(SP) phase growth. (B)Western blotting based detection of c-Myc-SarA
chimeric protein from sarA and ΔsarA harboring plasmid pKLA40; lysates
collected during mid-exponential (ME), late-exponential (LE), and stationary
(SP) phase growth. (C) SDS-PAGE and silver staining of exoproteins puriﬁed
from wild type, ΔsarA and ΔsarA harboring plasmid pKLA40 stationary phase
culture supernates. (D) RNA immunoprecipitation (RIP) was performed by
capturing c-Myc-SarA protein cross-linked to nucleic acids. Successful
immunoprecipitation was conﬁrmed byWestern blotting of cell lysate (L),
lysate supernate (SN), wash (W), and elution (E) fractions with anti-c-Myc
antibody.
puriﬁed, treated with DNase, ampliﬁed, labeled, and applied to
a S. aureus GeneChip®. All RIP-Chip assays were performed in
triplicate for both KLA43 (ΔsarA c-Myc-SarA) and ΔsarA cells
(negative control). A transcript was considered to be bound by
c-Myc-SarA if its average signal intensity value was ≥ two-fold
in KLA43 cells as compared to the negative control. It should be
noted that as a prerequisite to performing RIP-Chip assays we
exploited SarA’s known ability to bind the hla promoter region
and the fact that the microarray used in this study contains inter-
genic regions representing gene promoters to determine whether
our experimental approach was appropriate for studying cellular
SarA-nucleic acid interactions. Results from ChIP-chip experi-
ments revealed that the signal intensity of the intergenic region
representing the hla promoter region exhibited a signal increase
beyond the established threshold (≥ two-fold) in samples from
KLA43 cells as compared to UAMS-929 cells, indicating that the
experimental approach was capable of detecting known in vitro
protein-nucleic acid reactions in vivo (data not shown).
RIP-Chip assays results indicated that cellular c-Myc-SarA is
capable of binding to a total of 115 RNA species, including eight
virulence factor transcripts (Supplemental Table S5 in Supplemen-
tary Material). Of the virulence factor transcripts bound by SarA
(Table 6), spa and arcB were also stabilized in a sarA-dependent
Table 6 |Virulence-associated transcripts bound by cellular c-Myc-SarA
Common
name*
Fold
change
†
mRNA
stability
‡
Description
arcB 8.3 Stabilized Ornithine carbamoyltransferase
pfoR 3.7 Destabilized Perfringolysin O regulator protein
rsbW 7.6 Anti-sigma B factor
SA0097 8.3 Destabilized Transcriptional regulator AraC/XylS
family
sarZ 2.7 SarA homolog
sbi 3.3 Destabilized IgG-binding protein
spa 4.2 Stabilized IgG-binding protein A
srtA 7.4 Sortase
*S. aureus strain N315 locus.
† Fold change of signal intensities present in c-Myc-SarA samples in comparison
to ΔsarA samples (p<0.05).
‡ Effect of sarA on transcript turnover.
manner in at least one of the growth phases studied here (late-
log and stationary phase) or by our laboratory previously (mid-
exponential phase; Roberts et al., 2006). Thus,our collective results
indicate that spa mRNA is stabilized in a sarA-dependent manner
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(Roberts et al., 2006) and that SarA protein is capable of bind-
ing the transcript during in vitro conditions and within bacterial
cells. When taken together, these results suggest that SarA may
post-transcriptionally regulate gene expression by binding to and
modulating the RNA degradation properties of target transcripts.
DISCUSSION
Staphylococci produce an array of TCRS and DNA-binding pro-
teins that are thought to modulate virulence factor transcript
synthesis, providing the pathogen with a means for sensing and
responding to environmental stresses including exposure to sub-
inhibitory concentrations of antibiotics (Novick, 2003). By deﬁn-
ition, transcript titers are a function of both transcript synthesis
and degradation, and mounting evidence strongly suggests that
orchestrated changes in mRNA degradation mediate the organ-
ism’s ability to regulate gene expression. Indeed, the global mRNA
degradation properties of S. aureus are signiﬁcantly altered in
response to growth phase, stringent response-inducing condi-
tions, and pH and temperature stress (Anderson et al., 2006,
2010;Olson et al., 2011). With respect to growth phase, RNA
turnover is rapid in exponential phase cells whereas a global stabi-
lization of RNA transcripts occurs during stationary phase growth;
∼90% of transcripts decay within 5min during mid-exponential
growth while only ∼50% of all transcripts decay within 5min
during stationary phase growth (Olson et al., 2011). Presently,
the factors that mediate this transition between RNA degrada-
tion proﬁles are poorly characterized. Because all transcripts do
not degrade at the same rate, it has been hypothesized that trans-
acting factors, such as RNA-binding proteins or regulatory RNAs,
may affect mRNA stability. Indeed, the mRNA turnover proper-
ties of nearly 150 exponential phase mRNA species, including the
cell surface-associated virulence factors spa and cna, have been
reported to be stabilized in a sarA-dependent manner (Roberts
et al., 2006). However, those studies were limited in scope, in
that the effects of sarA on RNA stability were only studied within
mid-exponential phase cells. In the present work, we evaluated
the effects of sarA on late-exponential and stationary phase RNA
turnover.
A comparison of mRNA turnover within wild type and ΔsarA
cells indicated that global RNA decay is similar between the
two strains; mRNA is rapidly degraded in late-exponential phase
cells but transcripts become more stable during stationary phase
growth. Despite these similarities, transcript turnover within each
growth phase was slightly decreased in ΔsarA cells indicating that
a product of the sarA locus affects the stability of a subset of mRNA
species. Indeed, sarA was found to both stabilize and destabilize
transcripts in each growth phase; 3.4 and 16.5% of transcripts
were stabilized, whereas 16.4 and 23.5% of transcripts were desta-
bilized in a sarA-dependent manner within late-exponential and
stationary phase cells, respectively. Among the stabilized tran-
scripts were those encoding for translation machinery, suggesting
that sarA may modulate protein production indirectly by post-
transcriptionally altering expression of the translation apparatus.
Perhaps more relevant to S. aureus pathogenesis, 19 virulence-
associated factors were stabilized in a sarA-dependent manner,
including cell surface components, secreted enzymes and toxins,
transcriptional regulators, and antibiotic resistance determinants.
Interestingly, a subset of these virulence factors, including spa,
hla, sak, and sspB have been previously shown to be regulated
by sarA at the transcriptional level (Cassat et al., 2006). These
results suggest that the effects of sarA on gene regulation in S.
aureus may be more complex than previously thought, and that
a product of the locus may post-transcriptionally regulate gene
expression.
The sarA locus is capable of producing three distinct tran-
scripts, each of which encode for and result in the production of
SarA protein. Thus, any potential post-transcriptional regulation
could occur via the SarA protein or via one of the transcribed
mRNAs as has been described with other regulatory RNAs in S.
aureus (reviewed in Felden et al., 2011). The mRNA turnover
properties of ΔsarA cells harboring plasmid-borne copies each
of these three transcriptional units demonstrated that their RNA
degradation propertiesmimicked one-another, suggesting that the
SarA protein (as opposed to a particular sarA transcriptional unit)
accounts for the sarA-dependent modulation of mRNA turnover
(data not shown). Thus, we predicted that SarA directly or indi-
rectly affects the RNA degradation properties of target transcripts.
Accordingly, gel-shift assays were performed to determinewhether
SarA protein directly binds to spa mRNA in vitro, a transcript that
is stabilized in a sarA-dependent manner. EMSA results revealed
that SarA alters the mobility of spa mRNA in a concentration-
dependent manner, suggesting that the protein is capable of bind-
ing the transcript in a cooperative manner. We hypothesize that
this may reﬂect two potential dynamic properties of the inter-
action: (1) SarA oligomerizes when binding RNA or (2) the spa
transcript contains multiple SarA-binding sites such that in the
presence of excess SarA the number of sites bound by the protein
are increased. Further, gel-shift assays indicated that SarA exhibits
a greater propensity to cause a higher molecular shift of the 5′-end
of spa mRNA, suggesting that either the 5′ end of the message
harbors a higher incidence of SarA-binding sites or that the sec-
ondary structure of the transcript’s 5′ end reduces the amount of
steric hindrance. Regardless, we conclude from the results of these
assays suggest that the SarA-mRNA interaction is not likely to be
equal across the entire length of the spa transcript.
In order to characterize the physiological relevance of SarA’s
potential RNA-binding properties, we performed in vivo RIP-chIP
assays to identify the transcripts with which the protein could
interact within bacterial cells. To do so, c-Myc epitope-tagged SarA
was expressed in ΔsarA cells and immunoprecipitated; c-Myc-
SarA-bound RNA molecules were subsequently identiﬁed using
GeneChips®. In total, SarA was found to interact with 115 mRNA
species, including eight virulence factors. Speciﬁcally, two of the
virulence factor transcripts that bound to SarA in vivo were also
found to be stabilized in a sarA-dependent manner, including the
spa transcript, anmRNA species that SarA appears to bind in vitro.
Taken together, these data suggest that SarA may alter the stability
of target transcripts by directly binding to these mRNA species,
which could, in-turn, limit the RNA molecule’s accessibility to
degradation machinery. Additionally, SarA also interacted with
three transcripts that are destabilized in a sarA-dependent man-
ner, suggesting that the protein:mRNA interaction may catalyze a
conformational change in the substrate RNA molecule that makes
it more susceptible to ribonuclease attack. In addition to ORFs,
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SarA also bound ﬁve transcripts that mapped to intergenic regions
and may represent non-coding RNA molecules.
Collectively, the data presented here indicate that SarA interacts
with RNA in a biologically relevant setting and that these inter-
actions correlate with alterations in the degradation properties of
a subset of those mRNA species. Thus, we hypothesize that SarA
post-transcriptionally regulates gene expression via binding to and
consequently modulating the mRNA turnover properties of target
transcripts. There is precedence for this prediction in other organ-
isms. For instance, in Escherichia coli, CsrA is an RNA-binding
protein that modulates virulence factor expression, in part, by
both stabilizing and destabilizing target transcripts. For instance,
CsrA associates with the 5′ untranslated region of the pgaA tran-
script, which blocks translation of the molecule and subsequently
destabilizes the transcript (Wang et al., 2005). CsrA has also been
shown to bind the ﬂhDC transcript, stabilizing the molecule and
ultimately contributes to bacterialmotility (Wei et al., 2001).Given
the similarities of CsrA and other RNA-binding proteins to SarA,
scenarios by which SarA can post-transcriptionally modulate gene
expression emerge. In the case of spa, whose transcript is stabilized
but protein production is repressed by SarA, binding of the RNA
may simultaneously inhibit activity of the translational machinery
and ribonucleases (RNases). This mechanism would presumably
provide the cell with a mechanism to repress protein A produc-
tion, in a manner that when inactivated would allow for efﬁcient
induction of Spa production without having to expend energy
to synthesize new transcripts. Our ﬁnding that SarA seems to
preferentially interact with the 5′ terminus of the spa transcripts
supports this prediction, as the 5′end of mRNA not only serves
as a potential entry point for the RNA degradation machinery,
it is also the loading site for the translation apparatus. Similarly,
the binding of SarA to transcripts which are normally stabilized
and for which protein levels are increased, SarA could function by
inhibiting degradationof the transcript byRNases, thus facilitating
increased production of protein. As what occurs with CsrA, SarA
also destabilizes transcripts that it binds in vivo, suggesting that this
interaction could expose transcripts to cleavage by RNases. It was
also observed that virulence factor transcripts that were stabilized
in a sarA-dependentmannerwere not bound by SarA in vivo (Sup-
plemental Table S5 in Supplementary Material). Thus, one can
assume that the modulation of RNA stability of these transcripts
is indirect; presumably, SarA regulates another factor, such as a
regulatory RNA or other RNA-binding protein, which ultimately
mediates the alteration in stability. While the biological signiﬁ-
cance of sarA-dependent control of mRNA stability is not yet fully
understood, these results indicate that SarA is an RNA-binding
protein with the potential to post-transcriptionally regulate the
mRNA and consequently protein production of target transcripts.
These results may have expanded signiﬁcance in that SarA rep-
resents a prototypical regulatory molecule with a multitude of
homologs within S. aureus and other bacterial pathogens.
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